PT3172227T - Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis - Google Patents

Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis

Info

Publication number
PT3172227T
PT3172227T PT158249557T PT15824955T PT3172227T PT 3172227 T PT3172227 T PT 3172227T PT 158249557 T PT158249557 T PT 158249557T PT 15824955 T PT15824955 T PT 15824955T PT 3172227 T PT3172227 T PT 3172227T
Authority
PT
Portugal
Prior art keywords
molecules
cells
treatment
autoimmune diseases
selectively activate
Prior art date
Application number
PT158249557T
Other languages
English (en)
Inventor
M Greve Jeffrey
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3172227(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of PT3172227T publication Critical patent/PT3172227T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PT158249557T 2014-07-21 2015-07-20 Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis PT3172227T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21

Publications (1)

Publication Number Publication Date
PT3172227T true PT3172227T (pt) 2019-12-06

Family

ID=55163946

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158249557T PT3172227T (pt) 2014-07-21 2015-07-20 Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis

Country Status (22)

Country Link
US (6) US20170037102A1 (pt)
EP (2) EP3172227B9 (pt)
JP (2) JP6768633B2 (pt)
KR (1) KR102493543B1 (pt)
CN (2) CN106795213B (pt)
AU (3) AU2015292889C1 (pt)
CA (1) CA2954847A1 (pt)
DK (1) DK3172227T3 (pt)
EA (2) EA202190903A3 (pt)
ES (1) ES2763198T3 (pt)
GB (1) GB2538666A (pt)
HU (1) HUE046065T2 (pt)
IL (3) IL289475B2 (pt)
LT (1) LT3172227T (pt)
MX (2) MX2017000821A (pt)
PL (1) PL3172227T3 (pt)
PT (1) PT3172227T (pt)
RS (1) RS59789B1 (pt)
SG (2) SG10202010158TA (pt)
SI (1) SI3172227T1 (pt)
WO (1) WO2016014428A2 (pt)
ZA (1) ZA201700344B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
SI3172227T1 (sl) * 2014-07-21 2020-02-28 Delinia, Inc. Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni
HUE043038T2 (hu) 2014-08-11 2019-07-29 Delinia Inc Regulator T-sejteket szelektíven aktiváló, módosított IL-2-változatok autoimmun betegségek kezelésére
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3280725B1 (en) * 2016-05-04 2020-08-26 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
EP3458095A4 (en) 2016-05-18 2019-11-27 Albert Einstein College of Medicine PD-L1 POLYPEPTIDE VARIANTS, T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USING SAME
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN110167957A (zh) * 2016-11-08 2019-08-23 德里尼亚公司 用于治疗自身免疫疾病的il-2变体
BR112019011799B1 (pt) 2016-12-13 2021-12-21 Delinia, Inc Proteína de fusão, proteína dimérica e composição farmacêutica
EP3558339B1 (en) 2016-12-22 2024-01-24 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
IL309479A (en) 2017-03-15 2024-02-01 Cue Biopharma Inc Methods for modulating an immune response
JP7001285B2 (ja) * 2017-03-29 2022-01-19 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20200097275A (ko) * 2017-12-06 2020-08-18 팬디온 테라퓨틱스, 인코포레이티드 Il-2 뮤테인 및 그 용도
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20200100098A (ko) 2017-12-19 2020-08-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
TW201930345A (zh) 2017-12-27 2019-08-01 日商協和醱酵麒麟有限公司 Il-2改型體
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
JP7464530B2 (ja) 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
EP3552738A1 (en) * 2018-04-12 2019-10-16 Sandvik Machining Solutions AB A method of producing an additive manufactured object
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
BR122021012517A2 (pt) 2018-08-06 2021-08-10 Medikine, Inc. Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3875475A4 (en) * 2018-12-21 2022-12-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. VARIANT OF HUMAN INTERLEUKIN-2 OR ITS DERIVATIVE
AU2020214812A1 (en) 2019-02-01 2021-09-23 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins
JP2022521723A (ja) 2019-02-15 2022-04-12 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
AU2020329216A1 (en) * 2019-08-12 2022-02-24 AskGene Pharma, Inc. IL-2 fusion proteins that preferentially bind ILl-2ralpha
IL292803A (en) 2019-11-05 2022-07-01 Medikine Inc Compounds that bind to both 2-il and 7-il receptors, preparations containing them and their uses
BR112022008744A2 (pt) 2019-11-05 2022-07-19 Medikine Inc Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
KR20220116513A (ko) * 2019-12-20 2022-08-23 리제너론 파아마슈티컬스, 인크. 신규 il2 작용제 및 이의 사용 방법
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
MX2022009390A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿¿c.
JP2023512687A (ja) 2020-02-03 2023-03-28 メディカイン、インコーポレイテッド ＩＬ－７Ｒα結合化合物
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
GB2602612B (en) 2020-05-13 2023-11-01 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
IL302114A (en) 2020-10-29 2023-06-01 Bristol Myers Squibb Co Fusion proteins for the treatment of diseases
TW202227123A (zh) 2020-11-13 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 一種包含人白細胞介素２變體或其衍生物的醫藥組成物及其用途
AR125263A1 (es) * 2021-03-31 2023-06-28 Hanmi Pharm Ind Co Ltd Nuevo conjugado de análogo de il-2 inmunoestimulante y su método de preparación
BR112023020597A2 (pt) 2021-04-09 2023-12-12 Selecta Biosciences Inc Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune
CA3233644A1 (en) 2021-10-06 2023-04-13 David Klatzmann Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
US7186804B2 (en) * 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
US7267960B2 (en) * 2003-07-25 2007-09-11 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
JP5535633B2 (ja) * 2006-09-29 2014-07-02 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
EP2382228B1 (en) * 2009-01-21 2020-08-26 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
SG174378A1 (en) * 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
CA2791383C (en) * 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
SI3489255T1 (sl) * 2011-02-10 2021-11-30 Roche Glycart Ag Mutantni polipeptidi interlevkina-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CA3093606A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
SI3172227T1 (sl) 2014-07-21 2020-02-28 Delinia, Inc. Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
AU2015292889B2 (en) 2020-02-27
LT3172227T (lt) 2020-02-10
IL250024B (en) 2020-11-30
US20170051029A1 (en) 2017-02-23
GB2538666A (en) 2016-11-23
JP2017527272A (ja) 2017-09-21
EP3172227B1 (en) 2019-09-04
MX2017000821A (es) 2017-08-18
CN106795213A (zh) 2017-05-31
EA201790213A1 (ru) 2017-06-30
SG11201700514SA (en) 2017-02-27
US20220112260A1 (en) 2022-04-14
EA202190903A2 (ru) 2021-07-30
RS59789B1 (sr) 2020-02-28
EP3172227A4 (en) 2017-12-20
AU2022204946A1 (en) 2022-07-28
US20210047382A1 (en) 2021-02-18
SI3172227T1 (sl) 2020-02-28
KR20170028938A (ko) 2017-03-14
CN114133456A (zh) 2022-03-04
JP2021006038A (ja) 2021-01-21
US20190375812A1 (en) 2019-12-12
IL278299B (en) 2022-02-01
HUE046065T2 (hu) 2020-01-28
US20170327555A1 (en) 2017-11-16
AU2015292889C1 (en) 2023-01-19
IL289475B2 (en) 2023-10-01
WO2016014428A3 (en) 2016-03-24
EP3172227B9 (en) 2020-01-08
CN106795213B (zh) 2021-12-07
EA038361B1 (ru) 2021-08-13
EP3587444A1 (en) 2020-01-01
IL289475A (en) 2022-02-01
US20170037102A1 (en) 2017-02-09
IL289475B1 (en) 2023-06-01
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
EP3172227A2 (en) 2017-05-31
MX2021000083A (es) 2021-03-25
IL250024A0 (en) 2017-03-30
JP6768633B2 (ja) 2020-10-14
SG10202010158TA (en) 2020-11-27
GB201615553D0 (en) 2016-10-26
ES2763198T3 (es) 2020-05-27
EA202190903A3 (ru) 2021-12-31
CA2954847A1 (en) 2016-01-28
WO2016014428A2 (en) 2016-01-28
DK3172227T3 (da) 2019-12-02
KR102493543B1 (ko) 2023-01-30
PL3172227T3 (pl) 2020-04-30
ZA201700344B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
IL289475A (en) Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases
ZA201804458B (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HK1243001A1 (zh) 選擇性地活化調節性t細胞用於治療自身免疫病的修飾的il-2變體
HK1245827B (zh) 受控激活或消除治療性細胞的方法
IL249065A0 (en) Combination of treatments for cancer treatment
EP3227330C0 (en) TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
HUE053654T2 (hu) FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
IL249710A0 (en) Wastewater treatment system
PL3012014T3 (pl) Instalacja obróbki płynu
GB201414023D0 (en) Treatment of autoimmune diseases
GB201412441D0 (en) Treatment system
ZA201403183B (en) Effluent treatment system